Troponin T (TnT) is a useful biomarker for studying drug-induced toxicity effects on cardiac cells. In this paper, we describe how a surface plasmon resonance (SPR) biosensor was applied to monitor the release of TnT from active HL-1 cardiomyocytes in vitro when exposed to cardiotoxic substances. Two monoclonal human TnT antibodies were compared in the SPR immunosensor for analysing of the TnT release. The detection limit of TnT was determined to 30 ng/ml in a direct assay set-up and to 10 ng/ml in a sandwich assay format. Exposure of doxorubicin, troglitazone, quinidine and cobalt chloride to the cardiomyocytes for periods of 6 to 24 hours gave significant SPR responses, while substances with low-toxicity showed insignificant effects (ascorbic acid, methotrexate). The SPR results were verified with a validated immunochemiluminescence method which showed a correlation of r 2 = 0.790.
Introduction
Three troponin forms are released from heart muscle cells during cardiac injury: troponin T (TnT), troponin I (TnI), and troponin C (TnC) [1] . The release is caused by a combination of a disruption of the cardiomyocyte membrane and a dissociation of the thin-filament troponin complex in the cell [2] [3] .
This mechanism makes cardiac troponins sensitive clinical biomarkers for all heart muscle related diseases [4] [5] [6] [7] . It also makes the cardiac troponins useful as biomarkers when investigating cardiotoxicity effects induced by drugs [8] [9] [10] [11] [12] . In addition to that, troponins also are potential markers for testing of toxicants of other origin, such as cosmetic ingredients and other additives used in consumer products and which require more thorough testing according to new safety regulations [13] .
Biosensors have attracted significant interest for developing sensitive troponin assays. In particular surface-based immunosensors, such as surface plasmon resonance (SPR) [14] , total internal reflection fluorescence and surface acoustic wave sensors [15] provide a powerful assay format due to their ability to capture protein analytes by specific antibodies raised towards distinct epitopes [16] in rapid and parallel analytical setups.
For troponins SPR has been applied for analysis of the cardiac troponin I form (cTnI) in clinical blood samples [17] using conventional SPR instrumentation as well as fibreoptical SPR devices [18] . SPR has for this purpose also been applied to cTnT [20] [21] and TnC analyses [22] . These assays were developed to facilitate rapid and more specific methods compared to existing ELISA based methods (e.g. Elecsys [16] ).
For the analysis of drug-induced cardiotoxicity effects troponins are not exploited, except a few recent reports [9, 23] . For in vitro toxicity assaying this requires testing system, with relevant cardiac cells exhibiting a typical pacemaker phenotype [e.g. 24], i.e.
showing beating rates characteristics of ventricular cardiomyocytes and which can be monitored in close proximity to a sensitive analytical device. In particular biosensors have appropriate analytical attributes for this purpose -being adaptable to miniaturization, allowing rapid sampling and specific detection, having the potential of simultaneously analyzing several analytes (biomarkers) and compensating for changing media background during culture testing. conduit flow systems. Also, the SPR chips have the advantage of allowing parallel online analysis, and can be further expanded into multi-protein microarray devices as has been shown recently [25] .
To our knowledge, SPR has not yet been applied to drug-induced cardiotoxicity testing.
In this paper, we demonstrate the use of the SPR technique for testing a few well-known cardiotoxic compounds on a beating cardiomyocyte cell line, HL-1, and compare the performance and sensitivity with an existing in vitro method.
coupled to the surface with a 10 min injection (150 µg/ml in 10 mM sodium acetate buffer, pH 4.5), followed by a 7 min injection of 1 M ethanolamine (pH 8.5) to block the remaining activated groups. The surface was washed 5 x 3 min with 10 mM glycine-HCl, pH 2.5. The immobilization levels of antibodies were 9,000-13,000 RU.
Toxicity testing protocols
Two testing protocols were used in the study. The first protocol used a direct immunoassay procedure were the TnT analyte was directly detected on the sensor chip after binding to the antibody ligand. In the second protocol a sandwich assay procedure was applied where a secondary antibody amplified the detection (cf. Fig. 1 ).
In both protocols HL-1 cells were seeded 20 h prior to drug exposure in 48-well plates at a density of 1. were withdrawn from the cells, centrifuged at 13,000g for 10 min, and immediately analyzed undiluted on SPR sensor chips prepared as described above.
The assayed biochips were continuously purged with a flow of HBS-EP at 5 µl/min into which samples was injected for 3 min.
When applying sandwich assay protocol, the sample injection was followed by a 3 min injection of indicated antibody (2 µg/ml in HBS-EP). The surface was regenerated by injection of 10 mM glycine-HCl pH 2. 
Statistical analysis
For cell-free experiments, the response from fresh solution (HBS-EP or complete supplemented Claycomb medium) was subtracted as background. For cell experiments, medium from untreated cells was used as background. Data from sandwich assays and drug testing are presented as means ± SEM. The interassay comparison was analyzed using linear regression.
Results and Discussion

Evaluation of antibodies against cTnT for SPR analysis
Three monoclonal antibodies against cTnT were evaluated for their usefulness as ligands in an SPR-based assay for testing drug-induced cardiotoxicity (see Fig. 2 ). The 1F11 and 1C11 antibodies are both reported to bind to a conserved region of cTnT, and therefore to recognize cTnT from several different species, including human and mouse. The 7G7
antibody recognizes a more variable region of cTnT, and is human-specific. Each of the three antibodies was immobilized in separate flow channels on an SPR sensor chip. The amount of immobilized antibody per channel was between 8,000 and 13,000 RU. A fourth flow channel on the same chip was first amine-activated and then deactivated with ethanolamine and used as reference surface.
Injection of 3 µg/ml of cTnT in complete Claycomb medium for 3 min resulted in typical SPR response curves for all three antibodies ( antibodies were estimated at 30 ng/ml, defined as background response + 2 standard deviations.
To compare the background effects on the SPR response signal of a typical growth medium designed for cardiomyocyte culturing, we performed spike-in experiments with cTnT dissolved in both the complete Claycomb medium and the SPR running buffer (HBS-EP) (Fig. 3) . As seen in the figure, the complete Claycomb medium gave an additional background response of approximately 100 RU regardless of cTnT concentration. The Claycomb medium had no effect on the detection limit.
Thus, the cTnT antibodies considered best suited for SPR assaying were antibody 7G7 and 1F11. As mentioned above, while the 7G7 antibody is human-specific, the 1F11 binds to a more conserved region of cTnT and recognizes cTnT from several different species. An assay using 1F11 will therefore be compatible with cell lines and primary cells from different origin. A benefit of this is that the same assay setup can be applied when analyzing and comparing preclinical toxicity data from animal with human trials.
The nonspecific adsorption of biomolecules from the cell culture medium gave a background signal of approximately 100 RU. This did not interfere with the antibody/antigen interaction and did not affect the detection limit. This background signal may vary between batches of media components. Therefore these factors need be kept constant within an experiment.
Sandwich assay
In an attempt to improve the performance of the assay, we investigated whether a sandwich design could lower the detection limit. Since cTnT is a 36 kDa protein, adding a secondary antibody of 170 kDa should greatly increase the response (cf. Fig 1) . The 7G7 mAb was immobilized on the surface followed by injection of cTnT for 3 min (Fig.   4a ). The 1F11 mAb was then injected for 3 min. The response measured after the mAb injection was approximately 2.5 times higher for all concentrations compared to cTnT only. Injection of 1F11 without a prior injection of cTnT gave a background response of 8 RU, which was subtracted from the sandwich assay values above. Using 1F11 as immobilized capture antibody and 7G7 as secondary antibody gave similar results (Fig.   4b ). Using this sandwich assay, the detection limit was improved to10 ng/ml.
Thus, the sandwich assay with 7G7 and 1F11 increased the response and improved the detection limit three-fold; however, this approach could only be used for human cardiomyocytes since 7G7 is human-specific.
cTnT stability and measurability over time
We investigated the influence of the sample storage time before analysis of the cTnT samples. Aliquots of cTnT were added to complete supplemented Claycomb medium.
These were stored at + 20 °C, + 4 °C, and -70 °C for 24 hours. Fresh samples were then prepared, and all samples were analyzed by SPR (Fig. 5) . Regardless of temperature, the samples stored overnight gave significantly lower responses than freshly-prepared samples. Similar results were observed using the Elecsys 2010 for cTnT analysis. All further cTnT measurements were therefore performed on fresh samples.
The cTnT measurability was strongly reduced when samples were stored, regardless of temperature and analytical method. This may have been caused by degradation as previously reported [27] , or the fact that cTnT can form tightly bound tetramers in vitro [28] which may block the antibody binding sites. Hessel et al. [2] showed a degradation of cTnT in cell culture medium after cell death and the formation of degradation products. The magnitude of signal loss we observed was similar to the loss of intact cTnT in their study after 24 hours.
Compound testing
Compounds with or without known cardiotoxic effect and the murine cardiomyocyte cell line HL-1 were used to investigate whether SPR analysis of cTnT released into the cell culture medium can be used as a measure of cardiotoxicity. The HL-1 cells were exposed to doxorubicin in a concentration range of 1.25-320 µM for 6 and 24 hours respectively, and analyzed on the SPR using the 1F11 mAb in a direct assay (Fig. 6 ). The response of medium from cells incubated without drug was subtracted as background. Cells incubated for 6 hours showed a response of 44 RU at the highest doxorubicin concentration only.
After 24 hours a dose-response curve was observed with a maximum response of 20 RU at a doxorubicin concentration of 20 µM. The response decreased at higher doxorubicin concentrations. This is most likely due to cTnT being released at a earlier time point and the loss of measurability described above.
The SPR responses from HL-1 cells exposed to troglitazone in the concentration range 1.25-160 µM for 24 h are shown in Fig. 7a , and quinidine in the concentration range 100-850 µM in Fig. 7b . The dose-response curve showed a maximum response of 20 RU at a troglitazone concentration of 80 µM, and 21 RU at a quinidine concentration of 550 µM.
Again the response decreased at higher compound concentrations. The effects of cobalt chloride in the concentration range 5-320 µM is shown in Fig. 7c . The maximum effect was 11 RU at 80 µM.
As a negative control we exposed HL-1 cells to non-toxic levels of ascorbic acid in the range 0.14-35 mM (Fig. 7d) and methotrexate in the range 5 nM to 295 µM (Fig. 7e) 
Interassay comparison of Biacore 2000 and Elecsys 2010
To validate the SPR assay, we made a comparison between SPR (Biacore 2000) and However, very recently a comparison between the fourth generation TnT and a highsensitive cTnT method was published that showed great variation in bias across the entire measurement range [29] . In the low concentration range (10-30 ng/L) the bias varied from ca 20-290 ng/L, and at higher concentrations the bias was less pronounced. This is probably due to different molecular forms of TnT are excreted into plasma when the cardiac infarction varies in magnitude and that these molecular forms are measured with different specificity. Also in acute myocardial infarction, the intact troponin subunits rapidly disappear from the circulation during the early hours after infarction, while immunoreactive troponin fragments remain [11] . Furthermore it could be noted that for cTnI, for which there are a number of instruments and methods available, including antibodies and calibrators from several manufacturers, the results vary 20-fold to 40-fold in the reported clinical investigations [1, 29] . We think that development of new SPR assays may in future studies contribute to the further understanding of these fundamental questions.
Conclusion
A novel SPR based assay for measuring cardiotoxicity using an actively beating cardiomyocyte cell line and cTnT as a biomarker was developed. As emphasized in this article, the SPR-based cTnT assay is particularly suitable for study of drug-induced cardiotoxicity. The concentration of cTnT in cell culture medium from HL-1 cells exposed to toxic compounds is well within the detection range of this method.
The efficiency and sensitivity of the method was demonstrated using four compounds of different toxicity and two non-toxic compounds. The benefits of SPR based assay methods are their short analysis time, no need for sample pre-treatment or labelling and that very small sample volumes are required. Also, SPR methods can easily be integrated into cell culture systems for automatic and on-line measurement.
When evaluating the cardiotoxicity of drugs, however, it is necessary to consider several myopathic effects; for example, effects related to angina, ventricular hypotrophy, and congestive heart failure conditions [6] . Also, the predictive value can be improved by monitoring the release of troponins and natriuretic peptides (ANP, BNP) in combination with other factors such as endomyocardial biopsy and heart rate variability [7] . Moreover, the release of troponins is associated with myocyte cell death, and has also been shown to be a predictive factor for cardiac dysfunction, particularly in children when measured serially.
Recent SPR methods allow parallel analysis using several antibody ligands, thus enhancing throughput and allowing fine-tuning for compensation for subtile epitope and media deviations [30] .
In this study we has demonstrated how SPR can be used as a platform for a cardiotoxicity assay based on one biomarker, cTnT. The applied system with four flow cells allows parallel assaying of up to three biomarkers (and one reference surface) to be analyzed in parallel. With high-throughput array-based SPR systems, the number of biomarkers that can be studied simultaneously increases drastically. The thin filament-bound troponins are released from the cardiomyocytes exposed to a toxic compound, as an effect of membrane disintegration and by dissociation of the thin filament-troponin complex. Extracellular cTnT is sampled and assayed by a direct or a sandwich assay on an SPR dextran-gold chip with immobilized antibody. Spike-in experiment with human cTnT in concentrations between 10 and 3000 ng/mL. 1F11 antibody was immobilized on the surface. Human cTnT was injected for 3 min at concentrations 10-100 ng/mL, followed by injection of 7G7 antibody for 3 min. The relative response was measured directly after cTnT injection (blue) and again after the 7G7 injection (red). The error bars represent mean values of n=3. 
